Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease)

References

• Tan S, Ruan L, Jin K, et al. Systemic Rosai-Dorfman disease with central nervous system involvement. Int J Neurosci. 2018;128(2):192–197.
   PubMed Web of Science ®Google Scholar
• Destombes P. Adénites avec surcharge lipidique de l’enfant ou de l’adulte jeune observées aux Antilles et au Mali (Quatre observations). Bulletin Société Pathologie Exotique. 1965;58:1169–1117.
   PubMedGoogle Scholar
• Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87 (1):63–70.
   PubMedGoogle Scholar
• Dalia S, Sagatys E, Sokol L, et al. Rosai Dorfman Disease: Tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014;21(4):322–327.
   PubMed Web of Science ®Google Scholar
• Alqanatish JT, Houghton K, Bond M, et al. Rituximab treatment in a child with Rosai-Dorfman disease and systemic lupus erythematosus. J Rheumatol. 2010;37(8):1783–1784.
   PubMed Web of Science ®Google Scholar
• Cohen-Barak E, Rozenman D, Schafer J, et al. An unusual co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: report of a case and review of the literature. Int J Dermatol. 2014;53(5):558–563.
   PubMed Web of Science ®Google Scholar
• Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7(1):19–73.
   PubMed Web of Science ®Google Scholar
• Lu D, Estalilla OC, Manning JT, Jr, et al. Sinus histiocytosis with massive lymphadenopathy and malignant lymphoma involving the same lymph node: a report of four cases and review of the literature. Mod Pathol. 2000;13(4):414–419.
   PubMed Web of Science ®Google Scholar
• Long E, Lassalle S, Cheikh-Rouhou R, et al. Intestinal occlusion caused by Rosai-Dorfman disease mimicking colonic diverticulitis. Pathol Res Pract. 2007;203(4):233–237.
   PubMed Web of Science ®Google Scholar
• Ambati S, Chamyan G, Restrepo R, et al. Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51(3):433–435.
   PubMed Web of Science ®Google Scholar
• Hassani J, Porubsky C, Berman C, et al. Intraperitoneal Rosai-Dorfman disease associated with clear cell sarcoma: first case report. Pathology. 2016;48(7):742–744.
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–2703.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007–3015.
   PubMed Web of Science ®Google Scholar
• Emile J, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim–Chester disease. Blood. 2014;124(19):3016–3019.
   PubMed Web of Science ®Google Scholar
• Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017;30(10):1367–1377.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567(7749):521–524.
   PubMed Web of Science ®Google Scholar
• Moyon Q, Boussouar S, Maksud P, et al. Lung involvement in Destombes-Rosai-Dorfman Disease: clinical and radiological features and response to the MEK inhibitor cobimetinib. Chest. 2019: pii: S0012-3692(19)34099-1.
   PubMed Web of Science ®Google Scholar
• Cohen Aubart F, Emile JF, Maksud P, et al. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim–Chester disease. Br J Haematol. 2018;180(1):150–153.
   PubMed Web of Science ®Google Scholar
• Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorfman Disease with activating KRAS Mutation – response to cobimetinib. N Engl J Med. 2017;377(24):2398–2399.
   PubMed Web of Science ®Google Scholar
• Shanmugam V, Margolskee E, Kluk M, et al. Rosai-Dorfman Disease harboring an activating KRAS K117N missense mutation. Head and Neck Pathol. 2016;10(3):394–349.
   PubMed Web of Science ®Google Scholar
• Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877–2890.
   PubMed Web of Science ®Google Scholar
• Ross AB, Davis KW, Buehler D, et al. Primary Rosai-Dorfman disease of bone: a report of two cases. Case Rep Radiol. 2019;2019:1720131.
   PubMedGoogle Scholar
• Cooper SL, Chavis PS, Fortney JA, et al. A case of orbital Rosai Dorfman disese responding to radiotherapy. J Pediatr Hematol Oncol. 2008;30(10):744–748.
   PubMed Web of Science ®Google Scholar
• Christopherson KM, Gunther JR, Hilal L, et al. Thirty year experience with Rosai Dorfman Disease treated with radiation, chemotherapy, and/or surgery. Int J Radiat Oncol. 2018;102(3):432.
   Web of Science ®Google Scholar
• Shaver EG, Rebsamen SL, Yachnis AT, et al. Isolated extranodal intracranial sinus histiocytosis in a 5-year-old boy. Case report. J Neurosurg. 1993;79(5):769–763.
   PubMed Web of Science ®Google Scholar
• Goyal G, Ravindran A, Young J, et al. Clinicopathological features, treatment approaches and outcomes in Rosai-Dorfman disease. Haematologica. 2019: pii: haematol.2019.219626.
   PubMed Web of Science ®Google Scholar
• Horneff G, Jurgens H, Hort W, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine. Med Pediatr Oncol. 1996;27(3):187–192.
   PubMedGoogle Scholar
• Ahsan SF, Madgy DN, Poulik J. Otolaryngologic manifestations of Rosai-Dorfman disease. Int J Pediatr Otorhinolaryngol. 2001;59(3):221–227.
   PubMed Web of Science ®Google Scholar
• Petschner F, Walker UA, Schmitt-Gräff A, et al. “Catastrophic systemic lupus erythematosus with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rituximab. Dtsch Med Wochenschr. 2001;126(37):998–1001.
   PubMed Web of Science ®Google Scholar
• Pagel JM, Lionberger J, Gopal AK, et al. Therapeutic use of rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Am J Hematol. 2007;82(12):1121–1122.
   PubMed Web of Science ®Google Scholar
• Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol. 2002;69(1):67–71.
   PubMed Web of Science ®Google Scholar
• Hinterleitner C, Steurer M, Dorfel D, et al. Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient. Ann Hematol. 2019;98(1):227–230.
   PubMed Web of Science ®Google Scholar
• Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014;61(3):479–487.
   PubMed Web of Science ®Google Scholar
• Sathyanarayanan V, Issa A, Pinto R, et al. Rosai-Dorfman disease: the MD Anderson cancer center experience. Clin Lymphoma Myeloma Leuk. 2019;9(11):709–714.
   Google Scholar
• Löhr HF, Gödderz W, Wölfe T, et al. Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha. Eur J Cancer. 1995;31A(13–14):2427–2428.
   PubMed Web of Science ®Google Scholar
• Le Guenno G, Galicier L, Fieschi C, et al. Dramatic efficiency of pegylated interferon in sinus histiocytosis with massive lymphadenopathy. Br J Dermatol. 2011;164(1):213–215.
   PubMed Web of Science ®Google Scholar
• Aouba A, Terrier B, Vasiliu V, et al. Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: towards a new therapeutic approach. Haematologica. 2006;91(12 Suppl):ECR52.
   PubMedGoogle Scholar
• Warrier R, Chauhan A, Jewan Y, et al. Rosai-Dorfman disease with central nervous system involvement. Clin Adv Hematol Oncol. 2012;10(3):196–198.
   PubMedGoogle Scholar
• Prendes BL, Brinkman WT, Sengupta AL, et al. Atypical presentation of extranodal Rosai-Dorfman disease. Ann Thorac Surg. 2009;87(2):616–618.
   PubMed Web of Science ®Google Scholar
• Goyal G, Young JR, Koster MJ, et al. The mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of Adult Patients with Histiocytic Neoplasms: Erdheim–Chester Disease, langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019;94(10):2054–2071.
   PubMed Web of Science ®Google Scholar
• Ragotte RJ, Dhanrajani A, Pleydell-Pearce J, et al. The importance of considering monogenic causes of autoimmunity: a somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. Clin Immunol. 2017;175:143–146.
   PubMed Web of Science ®Google Scholar
• Grabczynska SA, Toh CT, Francis N, et al. Rosai-Dorfman disease complicated by autoimmune haemolytic anaemia: case report and review of a multisystem disease with cutaneous infiltrates. Br J Dermatol. 2001;145(2):323–326.
   PubMed Web of Science ®Google Scholar
• Kaur PP, Birbe RC, DeHoratius RJ. Rosai-Dorfman disease in a patient with systemic lupus erythematosus. J Rheumatol. 2005;32(5):951–953.
   PubMed Web of Science ®Google Scholar
• Lopetegui-Lia N, Asad SD, Jafri SI, et al. Autoimmune DISEASES and Rosai-Dorfman disease coexist more commonly than expected: two case reports. Am J Case Rep. 2019;20:770–772.
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Buhl AM, Klausen P, et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 2002;99(4):1314–1319.
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24(13):2121–2143.
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359–7368.
   PubMed Web of Science ®Google Scholar